1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: ONC-2010-19, NCT01203787
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-045, NCT01347333
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA182-037, EUDRACT # 2008-008715-26, NCT00908752
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01981, E1208, ECOG-E1208, CDR0000657952, U10CA021115, NCT01004978
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01989, CALGB 80802, CDR0000659348, U10CA031946, NCT01015833
|
|
6.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: POLARIS2009-001, NCT01287585
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HCC-P3-11-01, NCT01387932
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TS-103, NCT01556490
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ197-A-U303, NCT01755767
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 69 Sponsor: Other Protocol IDs: 2012-0977, NCT01821963
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0404-20, NCT00243841
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-352, NCT00516165
|
|
13.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 04-101, R01 CA104524, NCT00669136
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 062010-150, NCT01264705
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-701, 2011-000752-41, NCT01271504
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110102, 11-C-0102, NCT01306058
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
19.
|
Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RA-2011-025, NCT01395030
|
|
20.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000720022, NCCTG-N1153, N1153, NCT01497444
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 12D.424, NCT01754987
|
|
22.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130046, 13-C-0046, NCT01766635
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000069336, PCI-IRB-0611014, PCI-IRB-000656, PCI-IRB-000871, NCI-V02-1701, NCT00039078
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SJCI015, Alison Calkins, MD, Matthew Berlet, MD, NCT00152087
|